Johnson and Johnson 2008 Annual Report Download - page 26

24
Ethicon Endo-Surgery, Inc. continued to
drive business growth in 2008 with a number
of strategic achievements in new and existing
markets. In March, the company submitted
a Premarket Approval application to the U.S.
Food and Drug Administration (FDA) for
the ® System, the first computer-
assisted personalized sedation (CAPS)
system. It is intended for use by physician/
nurse teams administering minimal to
moderate propofol sedation to patients
undergoing screening and diagnostic
procedures for colorectal cancer and
disorders of the upper gastrointestinal tract.
Building on its commitment to long-term
patient outcomes, Ethicon Endo-Surgery
received FDA approval for the ™
Adjustable Gastric Band-C, the newest
addition to the ™ Personalized
Banding Solution for weight reduction in
people suering from morbid obesity. The
™ Band-C oers a streamlined,
curved design, an expanded adjustment
range to accommodate larger patients and
a re-lockable closing mechanism for intra-
operative repositioning. In addition, the
 my™ program extends
the continuum of care through a web-based
interactive, one-of-a-kind support system
that guides patients on a path of lifestyle
changes to help them sustain weight loss.
Use of the  my™ program
starts before surgery and continues well after.
In October, Ethicon Endo-Surgery
advanced its rich history of investing in R&D
by completing the acquisition of SurgRx, Inc.,
a privately held developer of the advanced
bipolar vessel-sealing technology used in the
® family of devices. This acquisition
brings together two leading complementary
energy technologies in the rapidly evolving
global energy segment. The combined
portfolio of ® products and the
Ethicon Endo-Surgery ® line
of ultrasonic medical devices oers greater
functionality and exibility for diverse
surgical procedure requirements.


In late 2008, Johnson & Johnson acquired
Omrix Biopharmaceuticals, Inc., a fully
integrated biopharmaceutical company that
develops and markets biosurgical and
immunotherapy products. Omrix is expected
to operate as a stand-alone entity reporting
through Ethicon, Inc. The acquisition
provides Ethicon with an opportunity to
strengthen its presence in active, biologic-
based hemostats and convergent products
for various surgical applications.
Ethicon currently has exclusive U.S.
and European Union distribution rights for
™ Thrombin Topical (Human)
and ™ Fibrin Sealant (Human),
two active, biologic-based hemostats
manufactured by Omrix. Ethicon and Omrix
are also partnering on a Fibrin Pad product
candidate, currently in Phase II clinical
trials, as an adjunct to control mild
to moderate soft tissue bleeding.
In early 2009, Johnson & Johnson
completed the acquisition of Mentor
Corporation, a leading supplier of medical
products for the global aesthetic market.
Mentor is expected to operate as a stand-
alone business unit reporting through Ethicon.
The acquisition will provide Ethicon with an
opportunity to strengthen its presence in
aesthetic and reconstructive medicine while
expanding our capacity to provide physicians
with products that can restore patients’
appearance, self-esteem and quality of life.
Ethicon and Mentor are two companies
that are committed to bringing evidence-
based medicine and the highest standards of
quality to the aesthetic and reconstructive
medical device category, and both companies
share a commitment to science, health and
wellness. Mentor will become the cornerstone
of a broader Johnson & Johnson leadership
strategy for aesthetic medicine, serving both
consumers and medical professionals.



 Go to
www.realizeband.com to learn about real
people receiving support to achieve long-term
weight loss with the REALIZE™ Personalized
Banding Solution.
   
Medical Devices & Diagnostics
JOHNSON & JOHNSON 2008 ANNUAL REPORT